Raymond James analyst Daniel Tamayo downgrades CrossFirst Bankshares (NASDAQ:CFB) from Outperform to Market Perform.
Caribou Biosciences Presents New Preclinical Data On CB-012, An Allogeneic Anti-CLL-1 CAR-T Cell Therapy, At The 2023 AACR Annual Meeting
-- CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models --
-- CB-012 IND-enabling studies ongoing; IND submission in r/r AML planned for
